生物利用度
化学
药代动力学
药理学
三唑
合理设计
体外
麦角甾醇
毒性
体内
伊曲康唑
氟康唑
对接(动物)
酶
口服
铅化合物
抗真菌
代谢稳定性
生物活性
隐球菌
结构-活动关系
两性霉素B
广告
CYP3A4型
微生物学
微粒体
生物化学
酶抑制剂
毛霉病
作者
Zirui Luo,Yixiang Sun,Zixuan Gao,Nian Liu,Haoyu Zhang,Xin Su,Dongmei Zhao,Maosheng Cheng
标识
DOI:10.1021/acs.jmedchem.6c01073
摘要
The rapid emergence of drug-resistant invasive fungal infections (IFIs) necessitates novel, highly stable antifungals. Using iodiconazole as a lead, we employed metabolic site blocking and scaffold optimization to design a series of novel CYP51 inhibitors. Compound D27 ( CZx-243 ) emerged as the optimal candidate, exhibiting potent, broad-spectrum in vitro activity against Candida and Cryptococcus species, including fluconazole-resistant strains (MIC = 0.00625–0.25 μg/mL). Mechanistically, CZx-243 inhibited ergosterol biosynthesis, morphological transitions, and biofilms. Pharmacokinetic profiling revealed high microsomal stability ( t 1/2 > 120 min), excellent oral bioavailability ( F = 76.7%), and a manageable drug–drug interaction profile. In vivo, CZx-243 demonstrated an excellent safety profile (no acute toxicity at 500 mg/kg) and profoundly reduced the renal fungal burden in a fluconazole-resistant systemic murine infection model at an oral dose of merely 5 mg/kg. CZx-243 is a highly promising clinical candidate for drug-resistant IFIs.
科研通智能强力驱动
Strongly Powered by AbleSci AI